Navigation Links
Evotec AG: R&D Update on 16 October 2007 Live on the Internet
Date:10/9/2007

HAMBURG, Germany and OXFORD, England, October 9 /PRNewswire-FirstCall/ -- Evotec AG (Frankfurt Stock Exchange: EVT) is going to hold an R&D Update in London on Tuesday 16 October 2007 at 13.00 pm BST (14.00 pm CET, 08.00 am US time East Coast) which will be broadcast live on the internet.

Jorn Aldag, (President & Chief Executive Officer), Dr John Kemp, (Chief Research & Development Officer) and Dr Tim Tasker, (EVP Clinical Development) will provide an update on the status and development plans for Evotec's Clinical Programs and Discovery Projects. In addition, we are delighted to announce that Dr Michael G Kelly, (SVP Research & Development) at Renovis, will present the Renovis Pipeline Programs.

To join the audio webcast and to access the presentation slides you will find a link on our home page http://www.evotec.com shortly before the event.

For those who prefer to listen to the presentation via phone, please dial:

From Europe: +49(0)69-5007-1308 (Germany)

+44(0)20-7806-1956 (UK)

From the US: +1-718-354-1388

Pass Code: 2793143

The on-demand version of the webcast will be available on our website: http://www.evotec.com - Investors - Webcasts.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.

In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABAA receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer's disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation.

On 19 September 2007, Evotec announced that it has entered into a definitive agreement under which Evotec will acquire Renovis, a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of pain and inflammatory diseases.

Contact:

Evotec AG

Anne Hennecke

SVP, Investor Relations & Corporate Communications

Phone: +49(0)40-56081-286

Fax: +49(0)40-56081-333

E-Mail: anne.hennecke@evotec.com


'/>"/>
SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Merge unveils updated medical imaging software
2. Merge announces sofware updates, upcoming acquisition
3. Tech Digest: Merge eMed product updates; Renaissance Learning 3rd qtr results
4. Solinus updates MailFoundry anti-spam hardware, switching to Linux
5. Dane County mapping software updated, available to public
6. Wingra Technologies updates data migration software
7. Firstlogics mailing-address update system gains Postal Service certification
8. Lands End Debuts Updated Virtual Model
9. Internet-enabled niche markets take center stage
10. Emergence of Internet video is changing the regulatory landscape
11. Viewing the Internet as a free-for-all can be costly
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Partnering to fuel ... Ben Franklin Technology Partners of Southeastern Pennsylvania ... ("IHG"), the parent company of Independence Blue Cross; and ... announced their intentions for a $6 million funding initiative ... healthcare startups. Responding to a burgeoning economic ...
(Date:12/7/2016)... ... 2016 , ... ACEA Biosciences, Inc. presented today updated efficacy ... for its lead drug candidate, AC0010, at the World Conference on Lung Cancer ... the safety, antitumor activity, and recommended phase II dosage of AC0010 in T790M-postitive ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... it has become a Wonderware Certified System Integrator Partner. Huffman Engineering is ... Electric Software. , “The System Integrator Partner certification gives customers confidence that our ...
(Date:12/7/2016)... , Dec. 7, 2016 /PRNewswire/ - OncoQuest ... development and commercialization of immunotherapeutic products for the ... entered into an Antibody Manufacturing Development Program with ... , USA) for its oregovomab antibody product. Supported ... Phase IIb clinical study in ovarian cancer patients, ...
Breaking Biology Technology:
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
(Date:11/29/2016)... France , November 29, 2016 Nearly one ... Continue Reading ... ... is part of an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: ...
(Date:11/22/2016)... , November 22, 2016 According to the ... IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), ... published by MarketsandMarkets, the market is expected to grow from USD 10.74 ... CAGR of 16.79% between 2016 and 2022. ... ...
Breaking Biology News(10 mins):